2-Methyl-2-(phenylmethoxy)-1-propanamine | 114377-39-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Methyl-2-(phenylmethoxy)-1-propanamine
• 英文别名: 2-methyl-2-phenylmethoxypropan-1-amine
• CAS: 114377-39-8
• 化学式: C₁₁H₁₇NO
• 分子量: 179.26
• InChiKey: PZTKJGVUIPIWKA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Method of increasing bioavailability and/or prolonging ophthalmic action of a drug
  申请人：Sun Pharma Advanced Research Company Limited

  公开号：US10172852B2

  公开（公告）日：2019-01-08

  The present invention relates to a method of increasing the bioavailability and/or prolonging ophthalmic action of a drug, the method comprising instilling into the eye an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters having a D50 value of at least 2 micrometer and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometer to 900 nanometer. The present invention further relates to an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters have a D50 value of at least 2 micrometers and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometers to 900 nanometers.

  本发明涉及一种提高药物的生物利用度和/或延长药物眼部作用的方法，该方法包括向眼部灌注一种水悬浮液，该水悬浮液包含载药纳米树脂颗粒的可逆团簇，所述团簇的 D50 值至少为 2 微米，所述载药纳米树脂颗粒的粒度分布特征在于 D90 值为 70 纳米至 900 纳米。本发明进一步涉及一种水性悬浮液，该悬浮液包含载药纳米树脂颗粒的可逆簇，所述簇的 D50 值至少为 2 微米，所述载药纳米树脂颗粒的粒度分布特征在于 D90 值为 70 纳米至 900 纳米。
• METHOD OF INCREASING BIOAVAILABILITY AND/OR PROLONGING OPHTHALMIC ACTION OF A DRUG
  申请人：Sun Pharma Advanced Research Company Ltd

  公开号：EP3179982A1

  公开（公告）日：2017-06-21
• DRUG LOADED NANORESIN PARTICLES
  申请人：Sun Pharma Advanced Research Company Ltd

  公开号：EP3328361A1

  公开（公告）日：2018-06-06
• [EN] METHOD OF INCREASING BIOAVAILABILITY AND/OR PROLONGING OPHTHALMIC ACTION OF A DRUG<br/>[FR] MÉTHODE D'AMÉLIORATION DE LA BIODISPONIBILITÉ ET/OU DE PROLONGEMENT DE L'ACTION OPHTALMIQUE D'UN MÉDICAMENT
  申请人：SUN PHARMA ADVANCED RES CO LTD

  公开号：WO2016016908A1

  公开（公告）日：2016-02-04

  The present invention relates to a method of increasing the bioavailability and/or prolonging ophthalmic action of a drug, the method comprising instilling into the eye an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters having a D50 value of at least 2 micrometer and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometer to 900 nanometer. The present invention further relates to an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters have a D50 value of at least 2 micrometers and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometers to 900 nanometers.
• [EN] DRUG LOADED NANORESIN PARTICLES<br/>[FR] NANOPARTICULES DE RÉSINE CHARGÉES DE MÉDICAMENT
  申请人：SUN PHARMA ADVANCED RES CO LTD

  公开号：WO2017017699A1

  公开（公告）日：2017-02-02

  The present invention relates to nano-resin particles that are suitable for pharmaceutical use and their use in the pharmaceutical field. The present invention provides nano-sized resin particles having a particle size distribution characterized in that D90 value is between 200 nanometers to 900 nanometer and D10 value is not less than 50 nanometers, wherein the nano-resin particles are in pure form and safe for pharmaceutical use. The present invention further relates to pharmaceutical compositions comprising these purified nano-resin particles and their use in the treatment of diseases. The present invention further provides a process for preparing purified, nano-sized resin particles that are suitable for pharmaceutical use, the process comprising steps of: (i) washing an ion exchange resin and suspending in an aqueous liquid, (ii) subjecting the suspension of (i) to wet milling for a period such that the particles have a particle size distribution characterized in that the D90 value is between 200 nanometers to 900 nanometers and D10 value is not less than 50 nanometers, (iii) subjecting the suspension of (ii) to purification to remove impurities, (iv) drying the purified suspension to obtain nano-resin particles in the form of dry powder.